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Dravet syndrome is an epilepsy syndrome of infantile onset, frequently caused by SCN1A mutations or deletions. Its prevalence,
long-term evolution in adults and neuropathology are not well known. We identiﬁed a series of 22 adult patients, including
three adult post-mortem cases with Dravet syndrome. For all patients, we reviewed the clinical history, seizure types and
frequency, antiepileptic drugs, cognitive, social and functional outcome and results of investigations. A systematic neuropath-
ology study was performed, with post-mortem material from three adult cases with Dravet syndrome, in comparison with
controls and a range of relevant paediatric tissue. Twenty-two adults with Dravet syndrome, 10 female, were included,
median age 39 years (range 20–66). SCN1A structural variation was found in 60% of the adult Dravet patients tested, including
one post-mortem case with DNA extracted from brain tissue. Novel mutations were described for 11 adult patients; one patient
had three SCN1A mutations. Features of Dravet syndrome in adulthood include multiple seizure types despite polytherapy, and
age-dependent evolution in seizure semiology and electroencephalographic pattern. Fever sensitivity persisted through adult-
hood in 11 cases. Neurological decline occurred in adulthood with cognitive and motor deterioration. Dysphagia may develop in
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impact at several levels. Treatment changes improved seizure control even after years of drug resistance in all three cases with
sufﬁcient follow-up after drug changes were instituted; better control led to signiﬁcant improvement in cognitive performance
and quality of life in adulthood in two cases. There was no histopathological hallmark feature of Dravet syndrome in this series.
Strikingly, there was remarkable preservation of neurons and interneurons in the neocortex and hippocampi of Dravet adult
post-mortem cases. Our study provides evidence that Dravet syndrome is at least in part an epileptic encephalopathy.
Keywords: SCN1A;N a
+ channel; epilepsy; neuropathology; encephalopathy
Abbreviations: Cx43 = connexin 43; GFAP = glial ﬁbrillary acidic protein; HLA = human leucocyte antigen; Nav1.1 = voltage-gated
sodium channel type 1.1
Introduction
Dravet syndrome (severe myoclonic epilepsy of infancy; MIM
607208), ﬁrst described  30 years ago, is a severe epilepsy with
onset in infancy (Dravet, 1978; Dravet et al., 2005). Dravet syn-
drome includes severe myoclonic epilepsy of infancy and severe
myoclonic epilepsy of infancy-borderland, where one or two car-
dinal features of severe myoclonic epilepsy of infancy may be
missing. Dravet syndrome is characterized by onset of recurrent
febrile and/or afebrile hemiclonic or generalized seizures, or status
epilepticus, in a previously healthy infant, followed by appearance
of multiple seizure types generally resistant to anti-epileptic drugs
with developmental arrest or regression (Dravet et al., 2005;
Jansen et al., 2006; Wolff et al., 2006). Onset up to 15 months
of age may occur (Depienne et al., 2009b). Mortality may be up
to 15% by 20 years (Dravet et al., 2005).
Of the cases with Dravet syndrome, 70–80% are caused by
SCN1A mutations, 90% of which occur de novo (Depienne
et al., 2009b; Marini et al., 2009; Mullen and Scheffer, 2009).
Haploinsufﬁciency is thought to be the mechanism underlying
most cases (McArdle et al., 2008; Depienne et al., 2009b;
Mullen and Scheffer, 2009). Genetic modiﬁers (Meisler et al.,
2010) and environmental factors probably contribute to the vari-
able phenotype of patients with SCN1A mutations. Other genes
involved in Dravet syndrome include SCN1B (Patino et al., 2009)
and GABRG2 (Harkin et al., 2002). PCDH19 (Dibbens et al.,
2008; Depienne et al., 2009a) and SCN2A (Kamiya et al., 2004;
Shi, 2009) mutations, and deletions involving the chromosome 2q
SCN cluster (Pereira et al., 2004; Davidsson et al., 2008; Lossin,
2009; Meisler et al., 2010) have been reported in Dravet
syndrome-like syndromes.
SCN1A knockout or -in animal models of Dravet syndrome
manifest spontaneous seizures, motor deﬁcits, ataxia and prema-
ture death (Yu et al., 2006; Kalume et al., 2007; Ogiwara et al.,
2007; Tang et al., 2009; Martin et al., 2010). Sodium currents are
signiﬁcantly reduced in inhibitory interneurons in both hippocam-
pus and cortex, but less so in hippocampal pyramidal cells (Yu
et al., 2006; Ogiwara et al., 2007). In a knock-in mouse model
of Dravet syndrome, excitatory cortical pyramidal neurons were
shown to be mostly unaffected, while inhibitory cortical
interneurons had impaired sodium channel activity (Martin et al.,
2010). Reduced sodium currents in hippocampal and cortical
GABAergic interneurons led to altered ﬁring patterns and overall
hyperexcitability (Yu et al., 2006; Catterall et al., 2008; Tang
et al., 2009; Martin et al., 2010). The reduced expression of
voltage-gated sodium channel type 1.1 (Nav1.1) in Purkinje cells,
leading to abnormal sodium ﬂux, may contribute to ataxia
observed in animal models (Yu et al., 2006). Further parallels be-
tween animal models and human Dravet syndrome include sensi-
tivity to body temperature elevation, causing seizures and interictal
epileptiform discharges, and age dependence of seizure frequency
and severity (Oakley et al., 2009).
Immune-inﬂammatory mediators have received attention in epi-
leptogenesis, febrile seizures and some chronic epilepsies (Vezzani
and Granata, 2005; Ravizza et al., 2008; Vezzani et al., 2008).
Dravet syndrome may provide a model to advance understanding
of inﬂammation in epileptogenesis and fever as a seizure-
provoking factor (Baulac et al., 2004; Oakley et al., 2009). The
inﬂuence in Dravet syndrome of additional environmental factors
such as vaccination may provide another window into investiga-
tion of immune factors in epileptogenesis (Berkovic et al., 2006;
McIntosh et al., 2010).
In childhood, Dravet syndrome has been well studied. Dravet
syndrome is comparatively uncommon, with an estimated inci-
dence of 51:40000 children (Hurst, 1990; Dravet et al., 2005),
but important to diagnose because it is considered at least in part
an epileptic encephalopathy, though other factors may contribute
to outcomes (Ragona et al., 2011). Thus, seizures and frequent
epileptiform activity on EEG are held in part responsible for cog-
nitive, behavioural and other impairments (Dravet et al., 2005);
both seizures and interictal discharges are potentially treatable and
their control might improve outcomes in Dravet syndrome
(Scheffer et al., 2009). In contrast to this knowledge in children
with Dravet syndrome, the place of Dravet syndrome in adults
with epilepsy is less well understood. Dravet syndrome is
under-diagnosed and under-reported in adulthood (Scheffer
et al., 2009). For patients with chronic epilepsy who are
long-standing attendees at clinic, details of the early history may
become obscured, and the diagnosis of Dravet syndrome may not
be considered. The long-term course of Dravet syndrome has
therefore not been fully characterized, particularly in patients in
their forties and over.
We aimed to gather more information on Dravet syndrome in
adults in order to inform management. We undertook an obser-
vational study that was not intended to be a systematic study of
prevalence in adults with severe epilepsy. Using both post-mortem
Dravet syndrome in adults Brain 2011: 134; 2982–3010 | 2983and surgical brain tissue resources, we also aimed to undertake a
detailed systematic neuropathological investigation of Dravet syn-
drome. We hypothesized that in the long term, Dravet syndrome
would cause further broad neurological decline, and that years of
encephalopathy would eventually lead to associated brain tissue
damage and loss identiﬁable on neuropathological examination. By
analysing clinical and neuropathological data, we sought to deter-
mine if Dravet syndrome could still be considered an epileptic
encephalopathy later in life.
Materials and methods
This project was approved by the relevant local (Human) Research
Ethics Committees with appropriate consent, or assent from relatives
or legal guardians in the case of minors, adults with intellectual im-
pairment and study of post-mortem tissue.
Patient ascertainment and phenotyping
We included adult patients from National Hospital for Neurology and
Neurosurgery clinics. All available clinical and investigational informa-
tion was reviewed.
Genetic testing
Details of DNA extraction and molecular analysis of the SCN1A gene
with DNA sequencing and gene dosage analysis are given in the
supplementary material. Parents of patients with a mutation were
tested where possible with direct sequencing of the mutated SCN1A
region or multiplex ligation-dependent probe ampliﬁcation.
Genotype–phenotype analysis
The design of our study limits such analysis. We divided our cohort
into: (i) paediatric cases with Dravet syndrome, with death before 12
years; (ii) adult cases with Dravet syndrome with death after 45 years;
(iii) living adult Dravet patients; and (iv) living children with general-
ized epilepsy with febrile seizure plus. We looked at each of these
groups for type of SCN1A mutations, and distribution of SCN1A mis-
sense mutations.
Neuropathology
The whole brain of three adult post-mortem cases with Dravet syn-
drome [who all met established criteria for Dravet syndrome
(Commission, 1989)], two adult post-mortem disease controls with
hippocampal sclerosis and three adult post-mortem controls with no
known neurological disease were studied. Adult disease cases were
former residents at the National Society for Epilepsy, Chalfont
(Sander et al., 1993). As comparators for older post-mortem cases,
we studied four paediatric post-mortem cases with Dravet syndrome,
one anterior temporal lobectomy specimen from a child with intract-
able childhood epilepsy with generalized tonic–clonic seizures, left hip-
pocampal sclerosis, operated at 12 years and a SCN1A mutation
(referred to as SCN1A
+ surgical case; Livingston et al., 2009), and
one post-mortem brain from a child with severe febrile seizures in
the genetic epilepsy with febrile seizures plus spectrum. We also had
access to a brain biopsy obtained in childhood from an individual as-
certained as an adult (Case 4).
Studies were undertaken to look for subtle malformations, hippo-
campal sclerosis (using standard qualitative, quantitative and immuno-
histochemical examination), cortical neuronal loss (qualitative
examination), loss of speciﬁc cell populations (qualitative and
semi-quantitative immunohistochemistry for interneurons), abnormal-
ities of brainstem nuclei or tracts, distribution and quantitation of cells
labelled with antibodies to Nav1.1 and for evidence of inﬂammatory
and other disease processes [examination with antibodies to human
leucocyte antigen (HLA)-DR and connexin-43 (Cx-43)].
Formalin-ﬁxed post-mortem whole brains were sliced coronally
along the anteroposterior axis and each slice was carefully
re-examined for macroscopic abnormalities. Systematic histological
sampling using blocks of 5mm thickness were taken from several re-
gions where possible: frontal (F1/F2), parietal, temporal and occipital
cortex, insula, cingulate gyrus, cerebellum, hippocampus, amygdala,
thalamus, basal ganglia, midbrain, pons, medulla and spinal cord at
the cervical level. For two adult post-mortem cases with Dravet syn-
drome (Cases PM1/EP039 and PM3/EP099), additional blocks were
taken from medial and orbital frontal cortex (Brodmann areas 6, 8 and
11), and insula. For the paediatric post-mortem cases, available sample
blocks are shown in the supplementary material. Surgically resected
temporal neocortex and hippocampal tissues were available for the
SCN1A
+ surgical case.
All blocks were processed in alcohol then xylene and embedded in
parafﬁn within 1 week of sampling. Haematoxylin and eosin and Luxol
fast blue stains were performed on sections from all regions.
Immunohistochemistry was performed on the post-mortem hippo-
campal, frontal cortical (F1/F2), cerebellar, pontine, medullary and
spinal cord sections, and the surgically resected hippocampal and tem-
poral neocortical sections. Details of the techniques and primary anti-
bodies, including the panel used as markers of neurodegenerative
processes, are given in the supplementary material.
Quantitative analysis
Pyramidal cell density was stereologically evaluated in the hippocampal
cornu ammonis-1 and cornu ammonis-4 subﬁelds of the adult
post-mortem cases with Dravet syndrome and post-mortem hippo-
campal sclerosis controls. Areal Nav1.1-immunopositive counts were
also undertaken in the hippocampal formation (dentate gyrus, cornu
ammonis and subiculum) and one gyrus of the frontal cortex in the
same cases. To obtain more information on patterns of cell loss, given
that Dravet syndrome is considered an interneuronopathy (Mullen
and Scheffer, 2009), we undertook interneuron counts. Details of
methods are in the supplementary material.
Results
Demographic and clinical data are summarized in Table 1. Median
age at last follow-up for the 22 adult cases with Dravet syndrome
was 39 years (range 20–66 years). Detailed case histories of the
adult post-mortem cases are given in the supplementary material.
For 11 patients with Dravet syndrome, a close temporal relation
of seizure onset with vaccination (Table 1) was documented, as
previously described (Berkovic et al., 2006; McIntosh et al., 2010).
Family history
There was a family history of epilepsy and/or febrile seizures in
nine adult patients (Supplementary Table 3), and another adult
patient had a sibling who had had one isolated seizure. Case 20
comes from a family with genetic epilepsy with febrile seizures
plus. Case 6 has a 15-year-old sister with microcephaly,
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Dravet syndrome in adults Brain 2011: 134; 2982–3010 | 2987quadriparesis, profound cognitive impairment and spasms, who is
on anti-epileptic drugs, but does not carry the SCN1A mutation
found in her brother (Case 6), nor SCN1A deletion or duplication.
Clinical condition and evolution in
adulthood
From onset in infancy, there was no period of seizure freedom
recorded. In two patients, recognition of a false ‘seizure-free
period’ in childhood led to anti-epileptic drug cessation, but
increased seizure severity and frequency led to recommencement
of anti-epileptic drugs, and in retrospect the parents could recog-
nize subtle seizures had never ceased to occur. All patients had
multiple anti-epileptic drugs with differential control of different
seizure types (Table 2), but not complete seizure freedom.
There was an evolution of seizure semiology and predominance
of certain seizure types with time (Supplementary Table 3). There
was no single pattern for seizure evolution for all patients.
All patients had multiple seizure types in adulthood (Table 1).
For 10 patients, seizures were mostly nocturnal and comprised
brief tonic or tonic–clonic seizures. Seizures were recorded in
video-EEG telemetry for 10 adults; seizures observed were com-
plex motor, dyscognitive, tonic or secondarily generalized with
focal EEG onset pattern or no recognizable EEG change.
Myoclonus was not prominent in adulthood, though its frequency
may have been under-reported. No adult patient in our series had
documented absences; all ‘absence-like’ (dyscognitive) seizures re-
corded in adulthood had focal EEG onset or no EEG change docu-
mented. Fever sensitivity persisted into adulthood, with even slight
variations of temperature sufﬁcient to trigger seizures in nine pa-
tients. No patient had any meaningful seizure-free period.
Non-convulsive status epilepticus was documented with EEG on
at least one occasion in seven patients. Triggers included
inter-current infections and slight increases in body or ambient
temperature.
Behavioural problems or ‘autistic-like’ features were observed at
some time of the evolution in most patients in our series (Table 1).
At last follow-up, the oldest living patient was 60 years of age.
Sixteen patients were in residential care; the remainder lived at
home with support. Neurological deterioration continued through-
out life in all patients, with further impairment of speech, mobility
and ability for daily activities (Table 1 and Fig. 1). Kyphoscoliosis
was documented in six patients. Cerebellar signs were found in
ﬁve patients, pyramidal signs in seven and extra-pyramidal in four
patients. Non-ictal urinary incontinence occurred late in the evo-
lution. The majority (18/22) of adult patients had severe intellec-
tual disability (as classiﬁed in McIntosh et al., 2010) at last
follow-up (Table 1).
Recurrent respiratory infections were documented in six pa-
tients. Dysphagia emerged as a late feature in ﬁve patients, docu-
mented in or after the fourth decade of life, leading eventually to
percutaneous endoscopic gastrostomy. One adult patient died
during the follow-up period from repeat aspiration pneumonia.
No post-mortem brain tissue was available for review from
this case.
Anti-epileptic drugs and non-pharmacological treatments are
listed for each case in Table 2, as well as changes to anti-epileptic
drugs after the diagnosis of Dravet syndrome was made, and their
impact on seizure control, cognitive function and quality of life.
Seven patients had already had drug changes instituted following
diagnosis, but in only three had sufﬁcient follow-up elapsed to
evaluate the effect of the changes. There was improvement in
seizure control even after years of drug resistance in three cases,
with signiﬁcant additional improvement in cognition and quality of
life in adulthood in two. In the four of the seven patients who had
had drug changes with a shorter period of follow-up, some early
indication of beneﬁt for some seizure types at least was apparent
in three (the one patient with no or minor change in seizure fre-
quency had stopped carbamazepine, but not yet started any new
anti-epileptic drug).
At last follow-up, most patients were on anti-epileptic drug
polytherapy. No patient was seizure-free, but in several cases sec-
ondarily generalized seizures were controlled with medication.
Causes of death in our adult series (Table 3) included three
cases of bronchopneumonia, and one case of sudden unexplained
death in epilepsy. In the paediatric Dravet syndrome group, three
died from sudden unexplained death in epilepsy and one had
global ischaemic brain injury; it is unclear for the latter case
whether there was a seizure followed by cardiorespiratory arrest.
No adult case in our series died of convulsive status epilepticus.
Neuroimaging ﬁndings
MRI with or without light sedation was successful in all but four of
the adult cases with Dravet syndrome. Most frequently, brain
imaging was normal, or showed non-speciﬁc ﬁndings, including
cerebral and cerebellar atrophy, or cerebellar atrophy alone
(Fig. 2A). One adult case with SCN1A mutation had unilateral
hippocampal sclerosis on MRI performed at 22 years of age
(Fig. 2B). Evidence of the anterior thalamotomy performed at
the age of 16 years was seen for Case 6 (Fig. 2C and D).
Electroencephalography ﬁndings
Serial EEG data were available for 21 adult patients. At least 1
seizure was recorded with video-EEG for 10 patients; seizure types
recorded included tonic, focal motor, dyscognitive and secondarily
generalized. Focal EEG features (Fig. 3A–D) were recorded in
17 of our adult cases. Ictal EEG onset was maximal in the fronto-
central regions in four cases (Fig. 3C).
Interictal EEG in all adult cases showed slow background activ-
ity. For 10 adults, childhood EEG data were available: four had
one previous EEG in early childhood with generalized epileptiform
discharges. No generalized epileptiform discharges were seen in
the EEGs in adulthood; focal features were seen (focal or multi-
focal interictal epileptiform discharges; focal ictal discharges;
Supplementary Table 3).
Non-convulsive status epilepticus was documented on
video-EEG in two patients, for whom subtle seizures with predom-
inant impairment of consciousness had previously been confused
with behavioural problems.
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Twenty adult patients had genetic analysis: SCN1A mutations
were found in 12 adult cases (Table 4; Figure 11). The mutations
were all different, and all but one patient had novel mutations.
One patient (Case 21) was found to have three SCN1A mutations,
which to the best of our knowledge has not been previously
described in the literature. We have not screened other genes
for mutations in our patients. For the four adults where both par-
ents have been tested, the mutations were de novo. We were
unable to extract DNA of adequate quality from formalin-ﬁxed
parafﬁn-embedded brain tissue for two adult cases (PM2/EP213
and PM3/EP099). Of the four paediatric post-mortem cases with
Dravet syndrome, two had SCN1A mutation, one had a whole
gene deletion and one was not found to have a mutation but
has not yet been checked for deletions. The two other paediatric
cases, one surgical case with intractable childhood epilepsy with
generalized tonic–clonic seizures, and one post-mortem case in the
genetic epilepsy with febrile seizures plus spectrum, both had
SCN1A mutations previously documented (Table 4).
Genotype–phenotype associations are summarized in Table 5. In
the paediatric Dravet post-mortem subgroup, we did not observe
missense mutations (Table 5); in the adult Dravet deceased sub-
group for whom genetic analysis was possible, 50% had an
SCN1A missense mutation. Both children with genetic epilepsy
with febrile seizures plus phenotype had missense mutations.
For the 17 adult patients living with Dravet syndrome, eight had
missense mutations. Additional information is provided in the
supplementary material.
Neuropathology
The macroscopic ﬁndings and results from histological and immu-
nohistochemical studies are summarized in Tables 3 and 6,
respectively.
Figure 2 Brain MRI ﬁndings in adults with Dravet syndrome and SCN1A mutation. Cerebellar atrophy (A, sagittal T1, Case 6) was a
feature in some cases. Case 21 was the only adult case with Dravet syndrome in our series with hippocampal sclerosis (left in this case)
evident on MRI (B, coronal T2). Case 6 had a stereotactic thalamotomy at the age of 16 years (C, sagittal T1 and D, coronal T2). Arrows
show the location of the main abnormalities in each image.
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The frontal cortex of two adult post-mortem cases with Dravet
syndrome (PM1/EP039 and PM2/EP213) showed an ordered and
preserved hexalaminar architecture with no neuronal cell loss,
similar to the frontal cortex of post-mortem controls with no
known neurological disease (Fig. 4A and B). The cortex in the
frontopolar, dorsal frontal and occipital regions of one adult
post-mortem case with Dravet syndrome (PM3/EP099) showed
a ‘micro-columnar’ architecture, with exaggeration of the vertical
alignment of cortical neurons (Fig. 4C), but these changes did not
amount to focal cortical dysplasia type I (Blu ¨mcke et al., 2011).
The cytoarchitecture of the parietal, temporal and occipital cortices
of all adult post-mortem cases with Dravet syndrome and controls
appeared normal, apart from cell loss observed in the upper cor-
tical layers of the parietal and temporal cortex of the hippocampal
sclerosis post-mortem control case (Control 2/EP296). The tem-
poral cortex of the SCN1A
+ surgical case was well preserved,
retaining hexalaminar architecture with no neuronal cell loss
noted.
The hippocampi of all adult post-mortem cases with Dravet
syndrome showed preservation of neurons in all cornu ammonis
subﬁelds, similar to post-mortem controls with no known neuro-
logical disease (Fig. 5A and B), and distinct from hippocampal
sclerosis post-mortem controls (Fig. 5C) and the SCN1A
+ surgical
case (Fig. 5D). Neuronal preservation in Dravet syndrome hippo-
campi was conﬁrmed by stereological quantiﬁcation of cresyl
violet-stained pyramidal cells in cornu ammonis-1 and cornu
ammonis-4 (Fig. 5E). The dentate gyrus of all adult post-mortem
cases with Dravet syndrome also appeared normal, with a distinct,
densely packed granule cell layer, as in post-mortem controls with
no known neurological disease (Fig. 5A and B). In contrast, the
granule cell layer of the hippocampal sclerosis post-mortem con-
trols and the SCN1A
+ surgical case showed dispersion of granule
cells into cornu ammonis-4 and dentate molecular layer (Fig. 5C
and D).
We investigated the interneuronal population within the
hippocampi of all adult post-mortem cases with Dravet syn-
drome using immunohistochemistry for calbindin, calretinin,
parvalbumin and neuropeptide Y. The appearance and localiza-
tion of the calbindin-, calretinin-, parvalbumin- and neuropeptide
Y-immunopositive interneurons in adult post-mortem cases with
Dravet syndrome were similar to that observed in the
post-mortem controls with no known neurological disease
(Fig. 10). While case numbers are obviously small, 2D counts of
calbindin-, calretinin-, parvalbumin- and neuropeptide
Y-immunopositive cells in cornu ammonis-1 and cornu ammonis-4
showed no clear difference between adult post-mortem cases with
Dravet syndrome and post-mortem controls (Fig. 5F), in keeping
with evidence of neuronal preservation in the Dravet syndrome
hippocampi on the basis of total cell counts. Other subcortical
structures (amygdala, thalamus, basal ganglia), of all adult
post-mortem cases with Dravet syndrome were intact.
Routine histological stains and calbindin- and parvalbumin
immunohistochemistry conﬁrmed cerebellar atrophy with Purkinje
cell loss and gliosis in all adult post-mortem cases with Dravet
syndrome (Fig. 6 and Table 3). Cerebellar atrophy (without
Figure 3 EEG ﬁndings. For Case 6, routine EEG showing
background of bilateral diffuse slow activity at 3–5Hz, and very
rare low amplitude sharp waves/spikes, more apparent in frontal
regions, right 4 left (A, bipolar montage). For Case 5, video–
EEG telemetry at the age of 26 years, showed bihemispheric
cortical dysfunction and bifrontal interictal epileptiform dis-
charges (B, bipolar longitudinal montage). Several complex
motor seizures were recorded, some with non-lateralized fron-
tocentral EEG onset (C, combined longitudinal and transverse
bipolar montage). Electrographic seizures were also recorded
with right posterior temporal pattern (D, bipolar longitudinal
montage).
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Dravet syndrome in adults Brain 2011: 134; 2982–3010 | 2995reported ataxia in life) was also noted in both hippocampal scler-
osis post-mortem controls (Control 1/EP296, Control 2/EP038),
and in one post-mortem control with no known neurological dis-
ease (Control 5).
The paediatric post-mortem case, PM23, showed mild bilateral
end folium gliosis only. For the other paediatric post-mortem
cases, only preterminal event-associated changes were found at
neuropathological examination of the brain with no other signiﬁ-
cant abnormality (Table 3).
Serial sections through the brainstem, including midbrain, pons
and medulla, of all adult post-mortem cases with Dravet syn-
drome, showed no signiﬁcant pathology. In two adult
post-mortem cases with Dravet syndrome, PM1/EP039 and
PM2/EP213 (Table 3), loss of myelin in the dorsal columns of
the medulla and cervical spinal cord was apparent (Fig. 7A).
Both cases had dysphagia and ataxia. Further immunohistochem-
ical investigation using CD68 and neuroﬁlament antibodies
showed focal macrophage inﬁltration (Fig. 7B) and axonal swelling
(Fig. 7C and D) in the pathological areas of both cases with Dravet
syndrome.
Immunohistochemistry
The frontal cortex (F1/F2), hippocampus and cerebellum of all
adult post-mortem cases with Dravet syndrome and controls,
and the temporal neocortex and hippocampus of the SCN1A
+
surgical case, were examined using immunohistochemistry for a
range of neuronal, interneuronal, inﬂammatory, vascular and
neurodegenerative markers. In particular, the frontal cortex
was examined as ictal electroclinical patterns suggested frontal
onset in several adult cases with Dravet syndrome (Fig. 3C and
Table 1).
Neocortex—neuronal and interneuronal markers
Neuronal nuclei-immunopositive neurons were organized in a
well-deﬁned, hexalaminar structure in the frontal cortex of all
adult post-mortem cases with Dravet syndrome or post-mortem
controls. No focal neuronal loss in the frontal cortex was evident
in any cases with Dravet syndrome and post-mortem controls with
no known neurological disease. Round, small to medium-sized
calretinin-, calbindin- and parvalbumin-immunopositive cells were
predominantly found in cortical layers II–IV of all adult
post-mortem cases with Dravet syndrome with similar distribution
and morphology to post-mortem controls (Fig. 8A–C; CR, CB and
PV). Neuropeptide Y-immunopositive cells and ﬁbres were
observed throughout the frontal cortex of all adult post-mortem
cases with Dravet syndrome and post-mortem controls (Fig. 8A–C,
NPY). In particular, one adult post-mortem Dravet syndrome case,
PM2/EP213, and both hippocampal sclerosis post-mortem controls
showed higher numbers of neuropeptide Y-immunopositive cells
and ﬁbres in the frontal cortex compared with post-mortem con-
trols with no known neurological disease. Nav1.1-immunopositive
pyramidal cells were detectable throughout the frontal cortex of all
adult post-mortem cases with Dravet syndrome (Fig. 9A), hippo-
campal sclerosis post-mortem controls and post-mortem controls
with no neurological disease. A population of small, intensely
labelled Nav1.1 cells was noted in the lower cortical layers and
in the white matter of all adult post-mortem cases with Dravet
syndrome and post-mortem controls (Fig. 9B). The number of
these intensely labelled Nav1.1-immunopositive cells in the grey
and white matter of the frontal cortex was not obviously different
between cases with Dravet syndrome, hippocampal sclerosis
post-mortem controls and post-mortem controls with no known
neurological disease (Fig. 9C). To conﬁrm the nature of intensely
Table 5 Genotype-phenotype analysis: SCN1A mutation type, and distribution of SCN1A missense mutations
Case ID Type of SCN1A mutation Distribution of SCN1A missense
mutations
Children with Dravet syndrome, death
between 2 and 11 years (n=4,
PM23–PM26)
Truncating—1 No missense mutation found
Whole-gene deletion—1
Splice site—1
No mutation, no result yet for deletion—1
a
Children with genetic epilepsy with febrile
seizures plus, one alive, 12 years, one
death at 5 years (n=2, 28 and PM27)
Missense—2 S4—2
Adults with Dravet syndrome, death be-
tween 46 and 66 years (n=4, PM1–PM3
and 16)
Missense—1 S4—1
No mutation, no deletion—1
No genetic analysis possible—2
b
Adults with Dravet syndrome, alive,
20–60 years (n=18, Patients 4–15 and
16–22)
Missense—8
c S4—2
Truncating deletion—1 S5–S6—1
Splice site —3
c S6—1
Insertion/deletion—1 Others—4
c
No mutation or deletion found—7 – S2—2
c
– DIII–DIV—1
– C-terminal—1
a For one child with Dravet, who died, the result was not available regarding the presence of deletion, after a negative mutation analysis.
b For two adults with Dravet, who died, it was not possible to perform genetic analysis on the post-mortem material.
c Patient 21 had three SCN1A mutations found, two missense and one splice acceptor.
D = (SCN1A protein) domain; genetic epilepsy with febrile seizures plus = genetic epilepsy with febrile seizures plus; S = (SCN1A protein) segment.
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Dravet syndrome in adults Brain 2011: 134; 2982–3010 | 2997labelled Nav1.1-immunopositive cells in the frontal cortex specif-
ically, double-labelling immunoﬂuorescent studies were underta-
ken with three different markers of interneurons (glutamic acid
decarboxylase, neuropeptide Y and parvalbumin), conﬁrming
that these cells are likely to be inhibitory cells (Fig. 9D–F).
Neocortex—connexin and inﬂammatory markers
Multipolar, connexin 43 (Cx43-) and glial ﬁbrillary acidic protein
(GFAP-) immunopositive cells were observed throughout the
frontal cortex of all adult post-mortem cases with Dravet syn-
drome and controls, particularly in the subpial regions and cortical
layer 1 (Fig. 8A–C). The distribution and morphology of
HLA-DR-immunopositive microglial cells in the frontal cortex of
all adult post-mortem cases with Dravet syndrome were similar
to post-mortem controls with no known neurological disease
(Fig. 8A and B, HLA-DR). In comparison, HLA-DR-immunopositive
cells in the frontal cortex of both hippocampal sclerosis post-
mortem controls appeared larger, more intensely labelled
(Fig. 8C, HLA-DR) and formed clusters.
Neocortex—vascular cells and neurodegeneration processes
von Willebrand factor-immunopositive blood vessels were
observed in all adult post-mortem cases with Dravet syndrome,
hippocampal sclerosis post-mortem controls and controls with no
known neurological disease, and the distribution and appearance
of immunopositive vessels were not markedly different between
cases (Fig. 8A–C, vWF). Immunohistochemistry using neurodegen-
erative process markers was not performed on frontal cortical
tissue.
The same panel of markers as used to study adult post-mortem
cases with Dravet syndrome showed that the temporal cortex of
the SCN1A
+ case retained a normal, hexalaminar cytoarchitecture
with no focal neuronal cell loss. There were a higher number of
neuropeptide Y-immunopositive cells and processes throughout
the temporal cortex of the SCN1A
+ case compared with
post-mortem controls with no known neurological disease, and
similar to immunolabelling evident in hippocampal sclerosis
post-mortem controls. The immunoreactivity of Cx43, GFAP,
HLA-DR and von Willebrand factor was not markedly different
between temporal cortex of the SCN1A
+ case and post-mortem
controls with no known neurological disease.
Hippocampus—neuronal and interneuronal markers
The expected loss of large calretinin-, calbindin-, parvalbumin- and
neuropeptide Y-immunopositive cells in the cornu ammonis-4
region, and loss of calbindin-immunopositive cells in the granule
layer, was detected in the hippocampus of the SCN1A
+ surgical
case and the hippocampal sclerosis post-mortem controls, but not
in any adult post-mortem cases with Dravet syndrome, or the
controls with no known neurological disease (Fig. 10A–C), again
demonstrating the preservation of neurons in this adult
post-mortem Dravet syndrome series. Immunoreactivity for dynor-
phin (DYN), a marker of mossy ﬁbre sprouting (Vezzani et al.,
1999; Thom et al., 2009), was not observed in the molecular
layer of the adult post-mortem cases with Dravet syndrome and
controls with no known neurological disease, but was present in
the SCN1A
+ surgical case and both hippocampal sclerosis
post-mortem cases (Fig. 10A–C; DYN). Nav1.1-immunopositive
labelling was observed in the hippocampal pyramidal and granule
cells of the cases with Dravet syndrome (Fig. 9B), and controls,
and the SCN1A
+ surgical case. A population of small, intensely
labelled Nav1.1 cells, similar to those noted in the frontal cortex,
Figure 4 Frontal cortex—histological staining. (A)
Haematoxylin and eosin shows the normal frontal cortex from
a post-mortem control with no known neurological disease.
(B) Cresyl violet shows the motor cortex of the adult Dravet
syndrome (DS) case, PM1/EP039, with good preservation of the
cortical laminae and Betz cells (arrow). (C) Cresyl violet and
Luxol fast blue show the frontal cortex from the adult
post-mortem Dravet syndrome case, PM3/EP099, with a focal
‘micro-columnar’ appearance (arrowheads to columnar align-
ment). Haematoxylin and eosin-stained section is 7mm thick
while Luxol fast blue and cresyl violet-stained sections are
14mm. Scale bar = 100mm.
2998 | Brain 2011: 134; 2982–3010 C. B. Catarino et al.was also found scattered throughout the hippocampal formation
(dentate gyrus, cornu ammonis subﬁelds and subiculum) of the
SCN1A
+ surgical case, adult post-mortem cases with Dravet syn-
drome and post-mortem controls. Quantiﬁcation of these cells re-
vealed that the number of small, intensely labelled Nav1.1 cells
was lower in the hippocampus compared with the frontal
cortex, within each case, but not markedly different between
adult post-mortem cases with Dravet syndrome, hippocampal
sclerosis post-mortem controls and controls with no known neuro-
logical disease (Fig. 9C).
Hippocampus—connexin and inﬂammatory markers
Cx43-immunoreactivity was not detected in the hippocampus of
any post-mortem controls with no known neurological disease
(Fig. 10A, Cx43). In contrast, Cx43-immunopositive cells were
observed in the cornu ammonis regions, particularly cornu
ammonis-4 and granule cell layer border, of adult post-mortem
cases with Dravet syndrome, hippocampal sclerosis post-mortem
controls (Fig. 10B and C, Cx43) and the SCN1A
+ surgical case.
The immunoreactivity of GFAP in the hippocampus of adult
post-mortem cases with Dravet syndrome and controls with no
Figure 5 Hippocampus, histological staining and interneuronal cell counts. Cresyl violet shows the normal hippocampus from a
post-mortem (PM) control with no known neurological disease (A), and the adult post-mortem case with Dravet syndrome (DS), PM2/
EP213 (B). In contrast, pyramidal cell loss in the left cornu ammonis-4 and granule cell dispersion are seen in the hippocampal sclerosis
post-mortem (PM HS) control (C), and the SCN1A
+ surgical case (D). (E) Stereological quantiﬁcation of cresyl violet-stained neurons
shows lower numbers of pyramidal cells in cornu ammonis-1 and -4 for hippocampal sclerosis post-mortem controls (Control 1 and 2
EP-HS) compared with adult post-mortem cases with Dravet syndrome (PM1–3) and post-mortem controls with no known neurological
disease (Controls 3–5). (F) Areal 2D counts of calbindin (CB), calretinin (CR), parvalbumin (PV) and neuropeptide Y (NPY)-immunopositive
cells in the cornu ammonis-1 and -4 show that the average number of hippocampal interneurons in the adult post-mortem Dravet
syndrome (n = 3) and controls with no known neurological disease (n = 2) is not markedly different. Refer to Fig. 10 (hippocampus
immunolabelling) for images of calbindin, calretinin, parvalbumin and neuropeptide Y immunoreactivities in the hippocampus of cases
with Dravet syndrome and controls. Scale bar = 50mm. CA = cornu ammonis; ML = molecular layer.
Dravet syndrome in adults Brain 2011: 134; 2982–3010 | 2999neurological disease was not markedly different (Fig. 10A and B,
GFAP); scattered GFAP-immunopositive cells were observed
throughout the hippocampal formation. GFAP-immunopositive
cells and a dense matrix of GFAP-immunopositive ﬁbres were de-
tected in the hippocampus of hippocampal sclerosis post-mortem
controls (Fig. 10C, GFAP) and SCN1A
+ surgical case. The distri-
bution and morphology of HLA-DR immunopositive microglial
cells in the hippocampus of Dravet syndrome and post-mortem
controls with no known neurological disease were similar, while
larger and more clustering of HLA-DR immunopositive cells
were observed in hippocampal sclerosis post-mortem controls
(Fig. 10A–C, HLA-DR) and the SCN1A
+ surgical case.
Hippocampus—vascular cells and neurodegeneration
processes
The immunoreactivity of von Willebrand factor was not markedly
different between adult post-mortem cases with Dravet syndrome,
controls (Fig. 10A–C, vWF), and the SCN1A
+ surgical case. There
were infrequent AT8-immunopositive neurons in the hippocampi
of all adult post-mortem cases with Dravet syndrome (all Braak
Stage 2 or less). There were no neuronal inclusions or plaques
noted with any of the markers in any adult post-mortem cases
with Dravet syndrome. Immunohistochemical labelling with mark-
ers for dementia and neurodegeneration (Supplementary Table 1)
of post-mortem Dravet syndrome hippocampi was not markedly
different from post-mortem controls.
Cerebellum—neuronal and interneuronal markers
Focal reduction in calbindin- and parvalbumin-immunopositive
Purkinje cells and dendrites was conﬁrmed in the cerebellum of
two adult cases with Dravet syndrome (PM1/EP039 and PM3/
EP099; Fig. 6A and B), both hippocampal sclerosis post-mortem
controls and one control with no known neurological disease
(Control 5). Loss of calbindin- and parvalbumin-immunopositive
Purkinje cells was only occasionally observed in the cerebellum
of the Dravet syndrome case, PM2/EP213. Calretinin-
immunopositive cells in the Purkinje and granule cell layers were
preserved in adult post-mortem cases with Dravet syndrome as in
controls. Similarly, small, parvalbumin-immunopositive cells were
retained in the Purkinje and molecular layers of all adult
Figure 6 Cerebellum, histological staining and immunolabelling. (A) Haematoxylin and eosin (H&E) shows a normal cerebellum from a
post-mortem control with no known neurological disease. The same stain shows Purkinje cell loss in the cerebellum of the adult
post-mortem Dravet syndrome case, PM1/EP039 (B), and a hippocampal sclerosis post-mortem control (C). The loss of Purkinje cells and
their processes, which normally extend into the molecular layer as observed in D, is evident in calbindin- and parvalbumin-immunolabelled
cerebellar sections from the case with Dravet syndrome, PM1/EP039 (E and F). Small, parvalbumin-immunopositive cells are still observed
in the molecular layer of the Dravet syndrome cerebellum (F, arrows). Scale bar = 100mm. ML = molecular layer.
3000 | Brain 2011: 134; 2982–3010 C. B. Catarino et al.post-mortem cases with Dravet syndrome, even in regions of cere-
bellar atrophy (Fig. 6F). Neuropeptide Y-immunoreactivity was not
observed in the cerebellum of any adult post-mortem cases with
Dravet syndrome or controls, except in one hippocampal sclerosis
post-mortem control (Control 1/EP296), which showed a small
number of neuropeptide Y-immunopositive cells and processes in
the granule cell layer. While Nav1.1-immunopositive Purkinje cells
were observed in the cerebellum of all cases (Fig. 9A), the small,
intensely labelled Nav1.1-immunopositive neurons, which were
observed in the frontal cortex and hippocampus, were not found
in the cerebellum of any adult post-mortem cases with Dravet
syndrome or post-mortem controls.
For the paediatric post-mortem cases with Dravet syndrome, the
cerebellum was preserved; in some cases, there were ‘acute’
changes related to pre-terminal cerebral events, and in one
(PM25), there was mild Purkinje cell loss (Table 3).
Cerebellum—connexin and inﬂammatory markers
A few Cx43-immunopositive cells were observed only in the cere-
bellar molecular layer of post-mortem cases with Dravet syndrome
and controls. GFAP- and HLA-DR-immunopositive cells were
mainly observed in the granule cell layer and white matter of
the cerebellum of post-mortem cases with Dravet syndrome and
controls. The distribution and appearance of these cells were not
markedly different between post-mortem cases with Dravet syn-
drome and controls. In post-mortem cases with Dravet syndrome,
PM1/EP039 and PM3/EP099, hippocampal sclerosis controls and
one control with no known neurological disease (Control 5) that
Figure 7 Brainstem and spinal cord—histological staining and immunolabelling. (A) Luxol fast blue (LFB) section shows a cord area with
myelin pallor in the dorsal column of the adult post-mortem Dravet syndrome case, PM1/EP039, where no myelin debris is observed.
(B) The same area immunolabelled with the CD68 antibody shows inﬁltration of CD68-immunopositive macrophages into the myelin
pallor. Neuroﬁlament immunohistochemistry shows axonal swelling in the spinal cord of the Dravet syndrome case, PM1/EP039, which is
presented here, in low (C) and high (D) magniﬁcation. The other Dravet case, PM2/EP213, shows similar ﬁndings as PM1, while the spinal
cord was normal for Dravet syndrome case PM3/EP099 (data not shown). Scale bar = 50mm( A and C); 25mm( B and D).
Dravet syndrome in adults Brain 2011: 134; 2982–3010 | 3001Figure 8 Frontal cortex—immunolabelling. The frontal cortex of a post-mortem control with no known neurological disease (A), the adult
post-mortem Dravet syndrome case, PM1/EP039 (B) and a hippocampal sclerosis post-mortem control (C) is immunolabelled with a panel
of interneuronal, inﬂammatory and vascular markers. The distribution and morphology of immunolabelled cells in the frontal cortex are
not markedly different between post-mortem cases with Dravet syndrome and controls. Apart from images of Cx43 and GFAP immu-
nolabelling, which are taken from subpial or layer I, images for all other markers are taken in frontal cortical layers II and III of the
post-mortem cases with Dravet syndrome and control. Scale bar = 50mm. CB = calbindin; CR = calretinin; NPY = neuropeptide Y;
PV = parvalbumin; vWF = von Willebrand factor.
3002 | Brain 2011: 134; 2982–3010 C. B. Catarino et al.Figure 9 Nav1.1-immunoreactivity in frontal cortex, hippocampus and cerebellum. (A)N a v1.1-immunolabelling is observed in the
cytoplasm of pyramidal cells in frontal cortex, hippocampal pyramidal cells, and cerebellar Purkinje cells, in all adult post-mortem cases
with Dravet syndrome. No Nav1.1-immunopositive cells are observed in sections that are incubated with primary Nav1.1 antibody solution
pre-mixed with control peptide. (B) A number of small, intensely labelled Nav1.1-immunopositive cells (arrows) are also found in the
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(continued)had marked Purkinje cell loss, GFAP and HLA-DR-immunopositive
cells were also observed in the cerebellar molecular layer.
Cerebellum—vascular cells and neurodegeneration processes
The immunoreactivity of von Willebrand factor was similar be-
tween all cases. Immunohistochemistry using neurodegenerative
markers was not performed in the cerebellum.
Brainstem
The immunoreactivities of the calcium-binding proteins, calretinin,
calbindin and parvalbumin, were not markedly different between
adult post-mortem cases with Dravet syndrome and controls.
Immunohistochemistry for GFAP, ubiquitin, -synuclein and
non-phosphorylated neuroﬁlaments did not reveal any pathologic-
al inclusions in the brainstem nuclei, neuronal loss or gliosis, in the
adult post-mortem cases with Dravet syndrome.
Discussion
Dravet syndrome is an important and paradigmatic epilepsy syn-
drome, being among the ﬁrst genetic epilepsy syndromes for
which the molecular basis has been unravelled, enabling functional
studies and animal models to reveal fundamental insights into the
underlying pathophysiology (Catterall et al., 2008). Dravet syn-
drome is thought to be underestimated in prevalence and
under-diagnosed in adults (Scheffer et al., 2009). There are
many gaps in the understanding of the clinical evolution of
Dravet syndrome in later ages, particularly after the fourth
decade of life, as for many years Dravet syndrome has been con-
sidered to be of the remit of the child neurologist. As children with
Dravet syndrome were prospectively followed, it became clear that
some did reach adulthood (Dravet et al., 2005). More recently,
adult patient series have been characterized (Jansen et al., 2006;
Akiyama et al., 2010), but most adults were under 35 years of age
at last follow-up. Surviving adults, over 35 years of age, with
Dravet syndrome may have missed out on a diagnosis as the syn-
drome was only described 30 years ago (Dravet et al., 1978) and
the diagnosis is often not considered in adult clinics.
We show that diagnosis even late(r) in life, in patients previously
labelled as having drug-resistant epilepsy with intellectual disability
of unknown cause, can carry important implications for affected
patients; rational treatment changes can be instituted, with possible
beneﬁt as we and others have shown, even after years of drug
resistance. In addition, recognition of the changes in language, cog-
nition, swallowing and gait, and determining whether speciﬁc
patterns exist, may help to improve diagnostic and prognostic
information and may reinforce a mandate for treatment changes.
We identiﬁed 22 adult patients with Dravet syndrome who had
not been diagnosed in childhood. Two-thirds were over 39 years
of age at last follow-up, a greater proportion than for other stu-
dies to date (Table 7). Two adult cases with Dravet syndrome
reached their sixties; survival to the seventh decade had not
been previously reported. Ours is not a systematic evaluation of
the prevalence of Dravet syndrome or SCN1A mutation in adults
with severe epilepsy, but an observational study of a highly se-
lected patient group from a tertiary centre. Together with the very
detailed clinical records available and the neuropathology evalu-
ation, this provided a unique opportunity for a study on the
long-term follow-up and outcome of adult patients with Dravet
syndrome.
Genotype–phenotype analyses are often complex (Kanai et al.,
2009; Scheffer, 2011; Zuberi et al., 2011), and more so in our
selected series. Caution is required in interpretation. Considering
the type of SCN1A mutations in the two extremes of age at
death, a pattern may seem to emerge: in the four children with
Dravet who died early, there were no missense mutations
(Table 5); of the patients who died after the age of 45 years,
out of the 2 in whom genetic analysis was possible, 1 had 1
SCN1A missense mutation, and the other was found not to
have an SCN1A mutation or deletion. No truncating mutations
were found in this group. Compared with published data,
there seem to be more missense than truncating SCN1A mutations
in the older Dravet group. We must emphasize limitations (ascer-
tainment bias; selection bias; small numbers; predominance
of paediatric cases in published data), but one could
hypothesize that missense mutations are more frequent in
patients with longer survival, testable with a prospective longitu-
dinal study.
We acknowledge important limitations in our study. Though it
includes some longitudinal data, it is a cross-sectional study. The
numbers of post-mortem cases are small. We were unable to
obtain DNA of sufﬁcient quality from the two older post-mortem
cases without a molecular genetic result (no frozen tissue was
available). Neuropathological analyses at other levels, for example
the electron microscopic, were not possible, as no appropriately
ﬁxed material was available. We cannot fully disentangle the nat-
ural history of Dravet syndrome and what may relate to other
aspects, such as the chronic effects of anti-epileptic drugs. We
note that for Unverricht-Lundborg disease, for example, previously
reported progressive neurological deterioration was later attributed
to the use of phenytoin (Eldridge et al., 1983); and avoidance has
meant life expectancy may approach normal (Kalviainen et al.,
2008). Despite these factors, the data available do generate new
insights.
Features of Dravet syndrome in adults include drug-resistant
seizures with a seizure repertoire that differs from that in child-
hood. Atypical absences and generalized interictal epileptiform
Figure 9 Continued
frontal lower cortical layers, frontal white matter, and hippocampal cornu ammonis-4, but not in the cerebellum. (C) The number of small,
intensely labelled Nav1.1-immunopositive cells in frontal cortex and hippocampus is not markedly different between cases with Dravet
syndrome, hippocampal sclerosis post-mortem controls and post-mortem controls with no known neurological disease. (D–F)
Double-labelled immunoﬂuorescent studies show small, intensely labelled Nav1.1 cells in the frontal cortex and hippocampi of cases with
Dravet syndrome co-express glutamic acid decarboxylase (D), neuropeptide Y (E) and parvalbumin (F). Scale bars = 10mm (A–C).
CA = cornu ammonis; GAD = glutamic acid decarboxylase; PCL = Purkinje cell layer; WM = white matter.
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series. In many of our adult patients, the predominant seizures are
nocturnal with focal semiological features and sometimes
secondary generalization; focal onset was often documented on
ictal EEG. This concurs with the ﬁndings of Akiyama et al. (2010),
whose recent series of adult Dravet syndrome showed 35/40
apparently generalized seizures had frontal origin, with or without
secondary generalization in the ictal EEG. No single clinical char-
acteristic in our series allowed the distinction between SCN1A
mutation-positive and -negative adult cases, but our numbers
are small for subgroup comparisons.
Although long life is possible, long-term functional, seizure-
related, cognitive and social outcomes appear unfavourable, with
cognitive and physical decline, gait disturbance and later dyspha-
gia, incontinence and increasing dependence for all activities of
daily life. We cannot say how earlier recognition and treatment
might inﬂuence these outcomes.
Dysphagia has emerged as a shared dysfunction in older cases
with Dravet syndrome. This is a novel observation in Dravet syn-
drome, and not a feature of other chronic epilepsies, except some
of the progressive myoclonic epilepsies, epilepsies associated with
cerebrovascular disease and Lennox-Gastaut ‘syndrome’ (Ogawa
et al., 2001). Dysphagia may manifest with unexplained cough, or
recurrent respiratory infections, which may lead to neurological
deterioration, and weight loss. Notably, for homozygous null
Scn1a
–/– knock-out mice, manual feeding extends survival
(Yu et al., 2006). Awareness and early diagnosis of dysphagia
may prevent complications, which include worsening of seizure
control, poor nutrition and ﬂuid intake, poor quality of life and
life-threatening aspiration pneumonia. The neuropathological basis
of the dysphagia is unclear, though visible changes in the brain-
stem were noted in two patients with Dravet syndrome and
dysphagia.
The neuropathology of human Dravet syndrome has not been
previously well characterized. To our knowledge, this is the ﬁrst
systematic neuropathological study in Dravet syndrome. We
included three adult and four paediatric post-mortem cases with
Dravet syndrome, and two other SCN1A mutation-carrying paedi-
atric cases with other syndromes. Several ﬁndings are of interest.
Patients with Dravet syndrome often have autism-like behav-
ioural features, and autism spectrum disorder has been associated
with seizures in the ﬁrst year of life (Saemundsen et al., 2008). In
a recent report, the neuropathological examination of one Dravet
paediatric case, who died of sudden unexplained death in epilepsy,
showed multifocal micronodular dysplasia of the left temporal
cortex and bilateral endfolium gliosis (Le Gal et al., 2010). We
did not ﬁnd other subtle malformation as reported in abstract
form by Hayashi et al. (2004). In one of our adult cases, there
was an exaggerated columnar architecture, or radial alignment of
neurons involving frontal and occipital regions. This patient had a
history of autistic spectrum disorder. Although studies in autism
have also described abnormalities of cortical minicolumns
(Casanova et al., 2010), neuropathological data in Dravet syn-
drome remain very limited; we simply make this observation,
but cannot draw general conclusions from our single case.
One adult case with Dravet syndrome had unilateral hippocam-
pal sclerosis on a MRI brain scan performed in his 20’s; his previ-
ous MRIs were not available for review. The SCN1A
+ surgical case
had unilateral hippocampal sclerosis. Previous studies have shown
that in a small proportion of patients with Dravet syndrome, hip-
pocampal sclerosis is observed (Striano et al., 2007a), and this
may not be present in the early childhood scans (Siegler et al.,
2005). Prospective MRI studies in Dravet syndrome are required. It
is of note that even on quantitative analysis, there was no neuro-
pathological evidence of neuronal loss in the post-mortem adult cases
with Dravet syndrome, showing that Dravet syndrome per se,
and SCN1A mutation (one post-mortem adult case with Dravet
syndrome), are not sufﬁcient to cause hippocampal neuronal loss
despite decades of drug-resistant seizures and recurrent episodes
of status epilepticus. Rarely, signiﬁcant clinical and imaging
Table 7 Adults with Dravet syndrome in the literature
Authors Number of cases aged
18 yrs or older
(total number in study)
Age range in
study (yrs)
Dravet syndrome
subtypes
SCN1A structural variation
Rossi et al., 1991 Not speciﬁed (15) 9-24 (mean 15) SMEI Not mentioned
Dravet et al., 2005 Not speciﬁed (105) 2.5-33.6 (median 11.5) SMEI and SMEB Not mentioned
Jansen et al., 2006 14 18-47 (median 26.5) SMEI and SMEB 10/14 mutations (+1 GABRG2
mutation)
Berkovic et al., 2006 2 17.5, 47 1 SMEI and 1 SMEB 2/2 mutations
Depienne et al., 2006 4 23–40 SMEI 4/4 mutations
Fujiwara et al, 2006 2 19, 19 SMEI Not mentioned
Striano et al., 2007a Not speciﬁed (58) 0.3–25 SMEI Not mentioned
Striano et al., 2007b Not speciﬁed (28) 3–23 (mean 9.4) SMEI Not mentioned
Zucca et al., 2008 1 28 SMEI 1/1 deletions
Kassai et al., 2008 Not speciﬁed (64) 3–20 SMEI Not mentioned
Akiyama et al., 2010 31 18–43 (median 22) 14 SMEI and 17 SMEB 25/31 mutations
Marini et al., 2009 2 26 and 30 SMEI One duplication exon 26, one ampliﬁ-
cation exon 26
Andrade et al., 2009 2 19, 34 SMEI Not mentioned
Ragona et al., 2010 Not speciﬁed (37) 0.5–28 (mean 16) SMEI 37/37 mutations
SMEB = severe myoclonic epilepsy of infancy-borderland; SMEI = severe myoclonic epilepsy of infancy.
Dravet syndrome in adults Brain 2011: 134; 2982–3010 | 3005Figure 10 Hippocampus—immunolabelling. The hippocampi of a control with no known neurological disease (A), the adult post-mortem
Dravet syndrome case, PM1/EP039 (B), and a hippocampal sclerosis post-mortem control (C), are immunolabelled with a panel of
interneuronal, inﬂammatory and vascular markers. The distribution and morphology of neuronal nuclei, calretinin, calbindin, parvalbumin,
and neuropeptide Y-immunopositive cells in the hippocampus are similar between the case with Dravet syndrome and post-mortem
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(continued)changes have been reported in Dravet syndrome following status
epilepticus (Sakakibara et al., 2009; Chipaux et al., 2010; Tang
et al., 2011). There may be age-dependent vulnerability of the
brain to injury induced by seizures (Haut et al., 2004), but it is
difﬁcult to separate out effects of seizures on the brain from the
effects of the disease process per se, and the effects of drugs and
other factors. It has been suggested that SCN1A mutation may
protect hippocampal neurons (Auvin et al., 2008), but more re-
search is needed to determine whether (and which, if any) SCN1A
mutations (or other causes of Dravet syndrome) are actually neu-
roprotective, and it should be noted that Dravet syndrome is not
primarily a hippocampal epilepsy.
Cerebellar atrophy was a frequent ﬁnding in cases with Dravet
syndrome but did not differ, either in pattern or distribution, to
that previously described in patients with chronic epilepsy without
Dravet syndrome (Crooks et al., 2000). The exact mechanism of
selective Purkinje cell loss, as well as the potential relationship to
observed ataxia, requires further study. In contrast to a previous
post-mortem report in a paediatric Dravet syndrome case (Renier
and Renkawek, 1990), no cerebellar dysplasia was seen in any of
our cases.
Vacuolar demyelinating myelopathy of the dorsal columns of
the cervical cord was noted in two patients with Dravet syndrome.
This is not a typical ﬁnding in patients with epilepsy, and although
a toxic or metabolic cause remains possible, future studies in pa-
tients with Dravet syndrome may elucidate if this is a feature
speciﬁc to Dravet syndrome. It is of interest that ataxia can be
observed in Dravet syndrome. More data are required to establish
whether the vacuolar myelopathy is its basis and whether such
myelopathy will respond to, or be prevented by, better seizure
control or modulation of Nav1.1 function; we note in passing
that Nav1.1 channels are expressed in white matter astrocytes
(Black et al., 1994) in close relationship with oligodendrocytes
(Waxman and Black, 1984).
We found no signiﬁcant alterations in the distribution and
morphology of inhibitory interneuronal subsets in cortex, cerebel-
lum, brainstem or hippocampus in adult Dravet syndrome, even
with quantitative analysis. The prevalence of small, intensely-
labelled Nav1.1-immunopositive cells was not different in adult
post-mortem cases with Dravet syndrome and post-mortem con-
trols with no known neurological disease. This, of course, does not
exclude putative functional abnormalities in any of these cell
types, as reported for the mouse models (Yu et al., 2006;
Ogiwara et al., 2007).
The clinical association between seizures and febrile episodes
was not underpinned by any evidence of persistent excessive
neuroinﬂammatory pathology or microglia in cases with
Dravet syndrome. Cx43, GFAP and HLA-DR immunoreactivities
in the frontal cortex were not different between adult
post-mortem cases with Dravet syndrome and controls. In the
hippocampus, higher numbers of Cx43-immunopositive cells in
adult post-mortem cases with Dravet syndrome and hippocampal
sclerosis post-mortem controls were observed, compared with
post-mortem controls with no neurological disease, where no
Cx43-immunolabelling was seen in the hippocampus. Previous
studies have suggested that the upregulation of Cx43 in medial
temporal lobe epilepsy with hippocampal sclerosis may facilitate
seizure propagation (Fonseca et al., 2002; Kielian, 2008). GFAP
and HLA-DR immunoreactivities were similar between adult
post-mortem cases with Dravet syndrome and controls with no
neurological disease, in contrast with a greater expression in hip-
pocampal sclerosis post-mortem controls. In the cerebellum, Cx43
immunoreactivity was similar between adult post-mortem cases
with Dravet syndrome and controls (low immunoreactivity). The
immunoreactivity of GFAP and HLA-DR is mainly observed in the
granule cell layer and white matter of adult post-mortem cases
with Dravet syndrome and controls, with higher immunoreactivity
in the molecular layer of cases, with loss of Purkinje cell and
processes.
Overall, we have not identiﬁed any histopathological hallmark
of Dravet syndrome. In fact, a striking feature was the conspicu-
ous preservation of neurons and interneurons, including within the
hippocampus, and cortex in the frontal, temporal and occipital
regions, despite decades of poorly controlled seizures. Where ex-
tensive changes were seen, in the paediatric post-mortem cases,
these were compatible with their agonal states; in the paediatric
sudden unexplained death in epilepsy cases, there were no neuro-
pathological abnormalities beyond changes common to chronic
epilepsy. Therefore, in neither paediatric nor adult post-mortem
cases, at the levels we examined the blocks available for study,
were there any pathological changes to explain the observed cog-
nitive/developmental arrest or decline.
Seizure freedom was not attained in any of our adult patients,
but seizure control was signiﬁcantly improved in the three cases
with sufﬁcient follow-up after speciﬁc post-diagnosis anti-epileptic
drug changes, with use of appropriate drugs and withdrawal
of others previously described to worsen control, such as
lamotrigine, carbamazepine, vigabatrin (Guerrini et al., 1998;
Figure 10 Continued
control with no known neurological disease, while expected loss of these cells is detected in the hippocampal sclerosis post-mortem
control. The immunoreactivity of dynorphin (DYN), a marker that demonstrates mossy ﬁbre sprouting, which is often associated with
hippocampal sclerosis, is intense in the inner to outer molecular layer of the hippocampal sclerosis post-mortem case but not in the case
with Dravet syndrome or the post-mortem control with no neurological disease. The immunoreactivity of Cx43, a gap junction marker that
has been reported to be upregulated in astrocytes from resected epileptic human brain tissue, is higher in the hippocampus of the case
with Dravet syndrome and the hippocampal sclerosis post-mortem control compared with the post-mortem control with no neurological
disease. The immunoreactivity of GFAP, HLA-DR and von Willebrand factor is not greatly different between cases with Dravet syndrome
and post-mortem controls, whilst GFAP and HLA-DR differ from the hippocampal sclerosis post-mortem control. Scale bars = 50mm.
CA = cornu ammonis; CB = calbindin; CR = calretinin; GCL = granule cell layer; ML = molecular layer; NeuN = neuronal nuclei;
NPY = neuropeptide Y; PV = parvalbumin.
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which may have different effects on different seizure types in
Dravet syndrome. Even if the patient had had drug-resistant seiz-
ures for many years, the suppression of at least one seizure type
was possible for at least several months, as also shown in a recent
report (Akiyama et al., 2010). For our oldest living patient, at 60
years, rational drug changes proved possible once the clinical diag-
nosis, with conﬁrmation from molecular genetics (which was im-
portant in this case given the lack of literature on long-term
features of Dravet syndrome), gave carers conﬁdence in such
anti-epileptic drug changes. A previous anti-epileptic drug
change had led to status epilepticus and strong reluctance to en-
tertain further changes. Subsequent drug changes led to signiﬁcant
beneﬁts, even after 60 years of drug-resistant seizures: convulsive
seizures were controlled and the patient began speaking again for
the ﬁrst time for over 5 years (Video in Supplementary material).
Dravet syndrome has been considered an ‘epileptic encephalop-
athy’ in the International League Against Epilepsy classiﬁcation
(Engel et al., 2001) and a syndrome carrying higher risk of epi-
leptic encephalopathy in the recent reorganization (Berg et al.,
2010), but controversy exists as to whether the seizures and inter-
ictal discharges themselves are responsible for the cognitive decline
(Dravet et al., 2005). Our data show Dravet syndrome is indeed at
least partly an epileptic encephalopathy: extensive neuropathology
has not shown any consistent cerebral structural abnormalities, cell
loss or other neurodegeneration, and clinically, even after many
decades of drug-resistant seizures, medication changes may im-
prove seizure control, and be associated with cognitive improve-
ment. Necessarily, the pathological components of our study are
cross-sectional, not longitudinal. We must therefore await
long-term follow-up of newly diagnosed infants and children
with Dravet syndrome, who are appropriately treated, to deter-
mine formally whether effective control of seizures and interictal
discharges prevents encephalopathy and other co-morbidities
(Scheffer et al., 2009)—not only cognitive decline, but also the
additional features that we and others have reported. However,
we have shown that the neurological substrate, at least at the
levels we have examined, appears largely intact and therefore po-
tentially capable of maintaining normal function—if seizures at
least can be controlled. That unexpected longevity is possible fur-
ther mandates efforts at earlier diagnosis and prompt effective
treatment. We also conclude that Dravet syndrome may be
found in older and younger adults and is a diagnosis that needs
consideration in this group, because it has management implica-
tions. Dravet syndrome is an important example of the value of
study of an apparently rare epilepsy, and the value of clinical
acumen in syndrome discovery and clinical diagnosis.
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Figure 11 Schematic representation of the SCN1A mutations found in our study (Table 4). SCN1A protein scheme adapted from
Harkin et al. (2007). The protein has four domains, I–IV, each consisting of six transmembrane segments, S1–S6. Circle = missense;
square = truncating; triangle = splice-site mutation; diamond = in-frame deletion. Positioning of the mutations within segments is
approximate.
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